LPL Financial LLC Increases Position in Novo Nordisk A/S (NYSE:NVO)

LPL Financial LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,362,782 shares of the company’s stock after buying an additional 47,496 shares during the quarter. LPL Financial LLC’s holdings in Novo Nordisk A/S were worth $162,266,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. 1620 Investment Advisors Inc. purchased a new position in shares of Novo Nordisk A/S during the second quarter valued at $25,000. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at $25,000. Gilliland Jeter Wealth Management LLC increased its holdings in shares of Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares during the period. Halpern Financial Inc. raised its position in shares of Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. Finally, Abound Wealth Management lifted its stake in shares of Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after purchasing an additional 157 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 2.4 %

Shares of Novo Nordisk A/S stock opened at $102.77 on Friday. The firm has a fifty day moving average price of $116.12 and a 200 day moving average price of $128.92. The stock has a market cap of $461.18 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15.

Wall Street Analyst Weigh In

NVO has been the subject of several analyst reports. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and an average price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.